The Bellingham Herald recently published an interview with Swedish Heart & Vascular Institute’s Mark Reisman, M.D., as well as his patient Mavis Arfman, recipient of the first MitraClip heart valve device in Washington state. Arfman is a resident of Bellingham.
'Heart & Vascular Institute' Swedish News Blog posts
Three-star rating awarded for exceptional cardiac surgery by the Society of Thoracic Surgeons
FOR IMMEDIATE RELEASE
Clay Holtzman, 206-386-2748, firstname.lastname@example.org
SEATTLE — Dec. 17, 2013 — Swedish announced today that its Cardiac Surgery Program has been awarded a “three-star” rating from the Society of Thoracic Surgeons (STS). A longstanding surgical leader in the Pacific Northwest, Swedish earned the top honor in coronary artery bypass graft surgery (CABG), aortic valve replacement surgery (AVR), as well as simultaneous surgery involving both procedures (AVR/CABG).
Swedish is among only 23 hospitals (or the top 2 percent of hospitals) across the country to achieve these quality metrics. Results are based on clinical outcomes of nearly 1,000 cardiac surgery programs, representing approximately 90 percent of all cardiac surgery centers in the United States.
“We are pleased to receive the STS three-star ratings for our CABG, AVR and AVR/CABG programs. This places Swedish in the top two percent of cardiac surgery programs in the U.S.,” says Glenn R. Barnhart, M.D., chief and executive director for Cardiac Surgical Services at the Swedish Heart & Vascular Institute. “The STS’s comprehensive rating system allows individuals and medical practices to compare the quality of cardiac surgery at hospitals across the country. Most importantly, it allows centers to objectively evaluate how they can improve patient care in the future. Our entire team of cardiologists, cardiac anesthesiologists, physician assistants, intensive care nurses and physician specialists, and operating room staff has earned this achievement.”
Swedish Medical Center Foundation Receives $10.1 Million Gift from The Robert and Jean Reid Family Foundation
With its largest gift, the Campaign for Swedish surpasses $128 million
FOR IMMEDIATE RELEASE
Contact: Clay Holtzman, Swedish, 206-386-2748, email@example.com
SEATTLE – Dec. 11, 2013 – The Swedish Medical Center Foundation announced today that it is receiving a gift of $10.1 million from the estate of Robert and Jean Reid that will support advanced cancer and cardiac care at Swedish. Funds from the gift will be distributed to the Swedish Foundation over many years through The Robert and Jean Reid Family Foundation.
The gift — the largest made during the $100 million Campaign for Swedish — will help to establish a core component of the Swedish Cancer Institute’s (SCI) Personalized Medicine Program: The Robert and Jean Reid Family Innovative Therapeutics & Research Unit. The Reid Family Innovative Therapeutics & Research Unit will aim to evolve cancer detection, diagnosis and treatment through advanced clinical research. For example, Swedish will test patient genes to better understand how a cancerous tumor might respond to a specific treatment. This is one step toward personalizing treatments and improving patients’ lives and outcomes.
“The new Reid Family Innovative Therapeutics & Research Unit will help position SCI as a national and international thought leader in personalized, molecular-based cancer prevention and therapy,” said Dr. Thomas Brown, executive director of the Swedish Cancer Institute.
Swedish Foundation Raises $100 Million to Help Meet Increasing Demand for Regional Health-Care Services
SEATTLE, Oct. 26, 2012 – Swedish Medical Center's seven-year fund-raising initiative, called The Campaign for Swedish, has raised $103 million, exceeding its initial $100 million fund-raising goal in approximately five-and-a-half years. The Campaign, launched to help improve patient care and treatment options throughout the Swedish system, is the largest fund-raising effort undertaken by the private, non-profit health system to date.
Swedish Heart & Vascular Institute Begins Offering a New, Minimally Invasive Aortic Valve Replacement Procedure
SEATTLE, Sept. 11, 2012 - For patients too sick to undergo open-heart surgery, a new, FDA-approved, minimally invasive aortic valve replacement procedure - now being performed by Swedish Heart & Vascular Institute (SHVI) providers - is offering new hope to patients whose life-threatening heart condition was previously inoperable.
SEATTLE, March 30, 2012 - Seattle NBC affiliate KING Television (Channel 5) aired a story during their 5 p.m. PT newscast tonight about a relatively new, FDA-approved medical device called LifeVest ®. The wearable defibrillator is a treatment option for sudden cardiac arrest that offers patients advanced protection and monitoring as well as improved quality of life.
LifeVest is the first wearable defibrillator. Unlike an implantable cardioverter defibrillator (ICD), the LifeVest is worn outside the body rather than implanted in the chest. This device continuously monitors the patient's heart with dry, non-adhesive sensing electrodes to detect life-threatening abnormal heart rhythms. If a life-threatening rhythm is detected, the device alerts the patient prior to delivering a treatment shock, and thus allows a conscious patient to delay the treatment shock. If the patient becomes unconscious, the device releases a Blue™ gel over the therapy electrodes and delivers an electrical shock to restore normal rhythm.